Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALDR

Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis

Alder Biopharmaceuticals logo

About Alder Biopharmaceuticals Stock (NASDAQ:ALDR)

Advanced Chart

Key Stats

Today's Range
$18.88
$18.88
50-Day Range
$18.88
$18.88
52-Week Range
$8.39
$19.12
Volume
N/A
Average Volume
5.12 million shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Receive ALDR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALDR Stock News Headlines

How Trade Wars Are Creating Fresh Opportunities for Investors
Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”
See More Headlines

ALDR Stock Analysis - Frequently Asked Questions

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) announced its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol-Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/07/2018
Today
5/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDR
Fax
N/A
Employees
202
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$296.43 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
11.73

Miscellaneous

Free Float
N/A
Market Cap
$1.58 billion
Optionable
Optionable
Beta
2.64
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ALDR) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners